UC Physicians, a large specialty physician group, seeks Tristate men to participate in a clinical trial of a drug that might prevent pre-cancerous lesions from developing into prostate cancer.

        More than 500 men at 60 medical sites nationwide are expected to join a study of acapodene, a prostate cancer drug made by Finland-based Orion Pharma.

        More than 198,000 American men are expected to be diagnosed with prostate cancer this year.

        In smaller trials, acapodene reduced the incidence of cancer by up to 50 percent. Now, scientists hope to match that success rate in a larger clinical trial, said Dr. Bruce Bracken, the urology professor at the University of Cincinnati who will be leading part of the study.

        Information: 558-4060.

Health plan rate increases here top U.S.
Owensby kin want federal inquiry
Officer recalled in Caton trial
Luken pursues mayor's post in eye of the storm
Luken's lead over Fuller growing, according to poll
Loans available for bootstrap businesses
Mediation effort has sixth session
Physician's group seeks men for trial
Police break down report's suggestions
Sailor ending tour in war zone
Tristate A.M. Report
HOWARD: Some Good News
Butler budgets court reports
Candidates keep busy with foul-play charges
Crisis center in fund crisis
Police chief apologizes after sex-harassment charge
Powder discovery halts Monroe mail
Salary critic supports mental health levy
Suburban employer finds workers in city
Suit asks return of seized horses
House OKs air security bill
Most of Ohio grant for games was spent
U.S. warns states on sex-offender laws
Crestview Hills TGIF wants to add 50 seats
Fire departments' merger discussed
Procedure for safe mail taught
Tax payments go electronic
UK director talks about attacks